Drugs and medicine – Scuba Dive Talks http://scubadivetalks.com/ Fri, 14 Jan 2022 06:00:45 +0000 en-US hourly 1 https://wordpress.org/?v=5.8 https://scubadivetalks.com/wp-content/uploads/2021/07/scuba.png Drugs and medicine – Scuba Dive Talks http://scubadivetalks.com/ 32 32 Nano therapeutic plans and new drugs https://scubadivetalks.com/nano-therapeutic-plans-and-new-drugs/ Fri, 14 Jan 2022 02:01:13 +0000 https://scubadivetalks.com/nano-therapeutic-plans-and-new-drugs/ Advances in technology have enabled medicinal chemists to discover and formulate several highly specific, biocompatible, and non-toxic therapeutic agents for clinical applications. Nanotechnology has made significant progress over the past decades and is crucial in all fields of science and technology. Nanotechnology-based pharmaceuticals offer multi-faceted and alternative methodologies to the limitations of many conventional clinical […]]]>

Advances in technology have enabled medicinal chemists to discover and formulate several highly specific, biocompatible, and non-toxic therapeutic agents for clinical applications. Nanotechnology has made significant progress over the past decades and is crucial in all fields of science and technology. Nanotechnology-based pharmaceuticals offer multi-faceted and alternative methodologies to the limitations of many conventional clinical therapies. Expertise in the design and development of nanoformulations has contributed to targeted drug delivery. Recently, the use of innovative therapeutic agents, especially in nanomedicine, has accounted for a large share of the global pharmaceutical market and is expected to continue growing rapidly in the near future. Nano Therapeutic Strategies and New Pharmaceuticals is an accessible, multi-part reference that informs the reader about several new techniques based on nanotechnology. The chapters explain in detail the relevant topics. The book is designed to encourage and assist undergraduate, graduate and graduate students in the field of nano-therapy, pharmaceuticals and bio-organic chemistry through the use of didactic language and simple illustrations. Part 2 of this book covers the potential of nano therapies and natural therapies for the treatment of neurological diseases, ion channel targeting, signal transduction therapy, gene therapy for single gene mutation diseases and for nano formulations for special purposes such as wound healing and stimulus-responsive drugs. delivery. The book also has a chapter that summarizes the types of nanoparticles suitable for specific molecular targets that mediate different diseases. The book set serves as a textbook for students of pharmacology and medical biochemistry, as well as a quick reference for bio-organic chemistry researchers, as well as general readers interested in nanomedicine.

Audience: Students in pharmacology and medical biochemistry, researchers in bio-organic chemistry, general readers interested in Nanomedicine

About the publishers:

Dr. Shahid Ali Khan completed his doctorate. in Nanocatalysis from King Abdulaziz University, Saudi Arabia and currently works as an assistant professor at the University of Swabi. Dr. Khan has supervised many MSC and MPHIL students, and many students are currently working in different areas of technology applications. Dr. Khan teaches various courses in organic chemistry, physical chemistry and spectroscopy to BS, MS and Ph.D. students and has published 5 book chapters and 63 publications with a cumulative impact factor of 260.

Dr. Saad Salman is a Lecturer in Department of Pharmacy, University of Lahore (Islamabad Campus) and teaches undergraduate and postgraduate students. He is a certified health researcher from NIH, USA. He has published over twenty-one international publications, two international books, two book chapters and thirty abstracts.

Dr. Al-Ghamdi received his doctorate. degree in Organic Chemistry, Polymers King Abdulaziz University, Jeddah, Saudi Arabia, in 2018. He joined the College of Science, Al-Zulfi Branch, Majmaah University, and currently heads the Department of Chemistry. Dr. Youssef O. Al-Ghamdi teaches various organic chemistry courses to BS students and he has published 20 research publications.

Keywords:

Blood-brain barrier, neurological disorders, neurovascular, bioavailability, chitosan, drug delivery, hydrogels, response to stimuli, flavonoids, nanotechnology, herbal medicine, gene delivery, channels, viral and non-viral vectors, voltage-gated channels.

For more information, please visit: https://bit.ly/3pJ7Yzg


Warning: AAAS and EurekAlert! are not responsible for the accuracy of press releases posted on EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

]]>
Alzheimer’s drug could find new target against superbugs https://scubadivetalks.com/alzheimers-drug-could-find-new-target-against-superbugs/ Wed, 12 Jan 2022 08:36:31 +0000 https://scubadivetalks.com/alzheimers-drug-could-find-new-target-against-superbugs/ Our antibiotics are failing in droves, threatening a future “dark age of medicine” where once simple infections are once again deadly. A team of scientists have now found a way to restore common antibiotics to their old strength, reusing a molecule developed to treat Alzheimer’s disease. Antibiotics have been one of the most important scientific […]]]>

Our antibiotics are failing in droves, threatening a future “dark age of medicine” where once simple infections are once again deadly. A team of scientists have now found a way to restore common antibiotics to their old strength, reusing a molecule developed to treat Alzheimer’s disease.

Antibiotics have been one of the most important scientific achievements of the 20th century, but unfortunately their effectiveness is running out. Bacteria have developed a consistent resistance to drugs over the decades, to the point that we are running low on effective antibiotics.

New drugs are regularly in development, but so-called superbugs are overtaking us, forcing scientists to come up with more creative solutions. One of the most promising avenues of research is to find ways to make old drugs effective again, by modifying them or combining them with elements such as blue light, gold nanoclusters, bacteriophages, probiotics, various molecules and peptides, or existing drugs designed for other diseases.

The breakthrough in the new study comes from the latter group. PBT2 is an investigational drug candidate developed to treat conditions like Alzheimer’s disease and Huntington’s disease, but clinical trials have proven to be disappointing. However, it could breathe new life into the war on superbugs, with the team taking advantage of the fact that PBT2 increases zinc concentrations.

“We knew from previous research that the immune system uses zinc as an innate antimicrobial to fight infections,” said Professor Christopher McDevitt, principal investigator of the study. “So we developed our therapeutic approach with PBT2 to use the body’s antimicrobial zinc to break down the antibiotic resistance of the invading bacteria. “

Combining the antibiotic ampicillin with the PBT2 molecule worked much better to clear infection from drug-resistant bacteria in the lungs of mice, compared to ampicillin alone.

University of Melbourne

The team tested the molecule against drug-resistant strains of common bacteria Streptococcus pneumoniae, and found that it again made the insects susceptible to a range of antibiotics. Follow-up experiments were carried out on mice with pneumonia, caused by a strain of the same bacteria resistant to the antibiotic ampicillin. Mice treated with ampicillin alone saw little change, but the infection was cleared for mice treated with ampicillin and PBT2 together.

While PBT2 may not have worked well against Alzheimer’s disease, clinical trials have at least shown it to be safe for humans, which the team says is a good step forward. . Further study is needed to prepare PBT2 for testing in humans as a potential treatment against superbugs.

The research was published in the journal Cell reports.

Source: University of Melbourne

]]>
Supreme Court upholds High Court order on plea alleging reuse of expired drugs, Supreme Court response on plea alleging reuse of expired drugs https://scubadivetalks.com/supreme-court-upholds-high-court-order-on-plea-alleging-reuse-of-expired-drugs-supreme-court-response-on-plea-alleging-reuse-of-expired-drugs/ Mon, 10 Jan 2022 08:53:25 +0000 https://scubadivetalks.com/supreme-court-upholds-high-court-order-on-plea-alleging-reuse-of-expired-drugs-supreme-court-response-on-plea-alleging-reuse-of-expired-drugs/ “It’s a waste of judicial time,” the judiciary observed orally, adding: “Sorry. This is a correct order.” New Delhi: The Supreme Court on Monday refused to interfere with an order issued by the Delhi High Court on a plea raising the issue of the alleged reuse of expired drugs by erasing original manufacturing details and […]]]>

“It’s a waste of judicial time,” the judiciary observed orally, adding: “Sorry. This is a correct order.”

New Delhi:

The Supreme Court on Monday refused to interfere with an order issued by the Delhi High Court on a plea raising the issue of the alleged reuse of expired drugs by erasing original manufacturing details and re-stamping them, saying that ‘it was a “correct prescription”.

In its order of February 27, 2020, the High Court refused to allow the request, observing that it appeared that there were sufficient provisions on the mode of labeling of drugs / drugs.

The High Court, while ruling on the plea, also stated that the petitioner was free to initiate appropriate proceedings in the appropriate forum for alleged violation of the relevant rules of the Medicines and Cosmetics Rules, 1945 with the relevant claims, claims and appendices.

The plea challenging the High Court order was heard before a bench by Judges Indira Banerjee and JK Maheshwari.

Lawyer Amit Sahni, who filed the petition, told the highest court that he initially filed a claim with the relevant authority on the matter and then filed a petition with the High Court. .

He said that one of the prayers in his plea filed in the High Court was to order the relevant authorities to take the appropriate steps to “replace the existing mechanism of stamping the drug strip with another method, namely printing, etc. to avoid or minimize re-use of expired drugs by re-stamping the new expiration date after erasing the existing manufacturing date / expiration date / price, etc.

“If there is something, it is necessary to lodge a complaint”, observed the magistracy, adding: “All the provisions are there”. Mr Sahni argued that there are provisions but the authorities are not implementing them to stop this.

The Supreme Court observed that if the authorities do not apply the provisions in a particular case, the applicant can then come and challenge the same.

“It’s a waste of judicial time,” the magistrate observed orally, adding: “Sorry. It is a correct order ”.

The judiciary said the High Court had “quite rightly” said that the petitioner could apply to the relevant authorities against any particular manufacturer or individual for alleged violation of the rules.

“We find no reason to interfere with the Delhi High Court judgment and order challenged in this SLP (request for special leave),” the magistrate said.

“As ruled by the High Court, as any violation is reported with specific details, action can be taken,” he said.

In his argument before the highest court, Mr Sahni said the case concerned an “extremely sensitive issue” relating to the failure to comply with Rule 96 of the Drug and Cosmetics Rules 1945, promulgated under the Drugs and Cosmetics. Act 1940, providing for the manner of labeling with indelible ink in a visible manner.

The plea alleged that the authorities concerned “do not take the appropriate measures to enforce the aforementioned rule and most pharmaceutical companies label drugs with a stamp (usually blue in color), which can easily be removed by a solution based on it. alcohol, that is to say aftershave. lotion, nail polish remover, etc.

(Except for the title, this story was not edited by NDTV staff and is posted from a syndicated feed.)


Source link

]]>
DTI, FDA urged to attack drug “grabbers” https://scubadivetalks.com/dti-fda-urged-to-attack-drug-grabbers/ Sat, 08 Jan 2022 16:44:31 +0000 https://scubadivetalks.com/dti-fda-urged-to-attack-drug-grabbers/ Health care advocate AnaKalusugan party list urged the Department of Commerce and Industry (DTI) and the Food and Drug Administration (FDA) to crack the whip on paracetamol and influenza drug grabbers in the United States. amid their unusual artificial shortage after the holidays. “There is nothing more criminal than piling up life-saving drugs in the […]]]>

Health care advocate AnaKalusugan party list urged the Department of Commerce and Industry (DTI) and the Food and Drug Administration (FDA) to crack the whip on paracetamol and influenza drug grabbers in the United States. amid their unusual artificial shortage after the holidays.

“There is nothing more criminal than piling up life-saving drugs in the midst of a raging pandemic. The DTI and the FDA must ensure that hoarding and profiting practices stop, ”said Ray Roquero, candidate on the AnaKalusugan party list.

“It is the government’s responsibility to ensure that everyone has equitable access to these essential medicines,” he added.

As COVID-19 cases continue to skyrocket during flu season, many have expressed concerns on social media about their difficulties purchasing paracetamol and the flu pills used to treat headaches, colds and fever, among others.

“We also call on consumers to buy only a reasonable amount of medicines, drugs and supplies, taking into account all members of the community. We should only buy drugs when it is clinically justified, ”the candidate from Anakalusugan said.

“Hoarding prevents the poor from accessing essential products like medicines and increases the prices of these products,” Roquero added.

The hoarding of drugs and medicines, as well as profit, are punishable under article 24 of the law of the Republic 9502 or the law of 2008.

Anyone or entity that violates this law could be jailed for five to 15 years or be fined 100,000 to 10 million pesos.

AnaKalusugan also called on drugmakers to speed up the restocking of branded and generic paracetamol at pharmacy level.

The Pharmaceutical and Healthcare Association of the Philippines (PHAP) said resupplying the drugs could take at least three more days.


Source link

]]>
Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-Driven Precision Drug Pipeline https://scubadivetalks.com/exscientia-and-sanofi-establish-strategic-research-collaboration-to-develop-ai-driven-precision-drug-pipeline/ Fri, 07 Jan 2022 06:00:00 +0000 https://scubadivetalks.com/exscientia-and-sanofi-establish-strategic-research-collaboration-to-develop-ai-driven-precision-drug-pipeline/ PARIS & OXFORD, England & BOSTON – (COMMERCIAL THREAD) – Sanofi and Exscientia today announced a groundbreaking research collaboration and licensing agreement to develop up to 15 new candidate molecules in oncology and immunology, leveraging the end-to-end AI platform at the end of Exscientia using samples from real patients. The companies have been working together […]]]>

PARIS & OXFORD, England & BOSTON – (COMMERCIAL THREAD) – Sanofi and Exscientia today announced a groundbreaking research collaboration and licensing agreement to develop up to 15 new candidate molecules in oncology and immunology, leveraging the end-to-end AI platform at the end of Exscientia using samples from real patients. The companies have been working together since 2016 and in 2019 Sanofi fired Exscientia’s new bispecific small molecule candidate capable of targeting two distinct targets in inflammation and immunology.

“We look forward to deepening our work with Exscientia, a leader in harnessing AI to modernize all aspects of drug discovery and development.” said Frank Nestlé, Global Head of Research and Scientific Director of Sanofi. “Sanofi’s collaboration with Exscientia aims to transform the way we discover and develop new small molecule drugs for cancer and immune-mediated diseases. Applying sophisticated AI and machine learning methods will not only shorten drug discovery times, but will also help design higher quality and better targeted drugs for patients. “

Exscientia and Sanofi will collaborate to identify and select target projects, building on Exscientia’s personalized medicine platform. The platform enables a “patient-first” approach by integrating primary human tissue samples into early target research and drug discovery. In doing so, Exscientia scientists can integrate patient, disease, and relevant clinical data into decisions about potential new drug candidates earlier in the drug creation process. In addition to target discovery, Exscientia will lead small molecule drug design and optimization activities through the nomination of development candidates, with Sanofi assuming responsibility for preclinical and clinical development, manufacturing and commercialization. .

“It is extremely exciting to work with Sanofi to realize the full potential of AI to deliver the next generation of cancer drugs and immunology” said Andrew Hopkins, DPhil, CEO and Founder of Exscientia. “Our AI-based platform can be leveraged in drug discovery, translational research and development, with applications ranging from improving precision medicine and the quality of drug candidates to enrichment for patient selection in clinical trials. Our expanded collaboration with Sanofi will use the breadth of our platform to test AI-designed drug candidates against patient tissue models, potentially offering much better accuracy than conventional approaches such as mouse models. When you consider the change this represents – testing candidates against real human tissue years before a clinical trial – it’s transformative.

Under the terms of the agreement, Exscientia will receive an initial cash payment of $ 100 million from Sanofi and will be eligible to receive future milestone payments for research, translation, clinical, regulatory and commercial development of up to approximately $ 5.2 billion in total, if all milestones for all programs are met. In the event that Sanofi commercializes a therapeutic product resulting from the collaboration, Exscientia will also be eligible to receive tiered royalties on product sales ranging from high to single digits through mid-adolescence and a co-investment option. clinic to increase the royalty rate up to 21% on net sales of co-financed products. The upfront cash payment of $ 100 million is expected to be reflected in Exscientia’s first quarter 2022 financial results as cash inflows from collaborations and recognized as revenue over the term of the agreement.

About Exscientia

Exscientia is an AI-driven pharmaceutical company committed to discovering, designing and developing the best possible drugs in the fastest and most efficient way. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to advance AI-designed small molecules in the clinical setting. Our pipeline demonstrates our ability to rapidly translate scientific concepts into precisely designed therapy candidates, with more than 25 projects underway, including the first three AI-designed drug candidates to enter Phase 1 clinical trials.

Exscientia has offices in Oxford, Vienna, Dundee, Boston, Miami and Osaka. For more information visit us on https://www.exscientia.ai or follow us on Twitter @exscientiaAI.

About Sanofi

Sanofi is committed to supporting people in their health challenges. We are a global biopharmaceutical company focused on human health. We prevent disease with vaccines, offer innovative treatments to fight pain and relieve suffering. We support the few people who suffer from rare diseases and the millions of people with long-term chronic diseases.

With more than 100,000 people in 100 countries, Sanofi transforms scientific innovation into healthcare solutions around the world.

Exscientia forward-looking statements

This press release contains certain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding Exscientia’s expectations regarding the capability of its personalized medicine platform based on AI to design and develop new candidate small molecules in oncology and immunology. Words such as “anticipates”, “believes”, “expects”, “intends”, “plans”, “anticipates” and “future” or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the uncertainties inherent in predicting future results and conditions, and no assurance can be given that the AI-backed personalized medicine platform described above will be successful in developing new small molecule candidates in the future. fields of oncology and immunology or to reach any stage of its agreement with Sanofi. Exscientia assumes no obligation to publicly update or revise forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Sanofi forward-looking statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations regarding future financial results, events, operations, services, product development and potential, and statements regarding performance. futures. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “believes”, “plans” and similar expressions. Although Sanofi management believes that the expectations reflected in these forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond Sanofi’s control. , which could cause actual results and developments to differ materially from those expressed, implied or projected by forward-looking information and statements. These risks and uncertainties include, among others, uncertainties inherent in research and development, in future clinical data and analyzes, including post-marketing, in decisions of regulatory authorities, such as the FDA or the EMA, regarding the whether and when to approve any drug, device or biological that may be filed for such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such product candidates, the fact that the product candidates, if approved, may not have commercial success, the future approval and commercial success of therapeutic alternatives, the ability of Sanofi to benefit from external growth opportunities, to carry out the associated operations and / or obtain regulatory authorizations, risks related to intellectual property and any pending litigation or related future and final outcome of such litigation, prevailing currency and interest rate trends, volatile market and economic conditions, cost containment initiatives and subsequent changes, and the impact that COVID- 19 will have on us, our customers, suppliers, vendors and other business partners, and the financial condition of any of them, as well as our employees and the world economy as a whole. Any significant effect of COVID-19 on any of the above could also negatively impact us. This situation is changing rapidly and additional impacts may arise that we are not currently aware of and may exacerbate other risks identified previously. Risks and uncertainties also include those uncertainties discussed or identified in public documents filed with the SEC and the AMF by Sanofi, including those listed under “Risk Factors” and “Caution Regarding Forward-Looking Statements” in the Sanofi annual report on Form 20 -F for the fiscal year ended December 31, 2020. Except as required by applicable law, Sanofi does not undertake any obligation to update or revise the information or forward-looking statements.



Source link

]]>
Doctors say lives lost in hospitals in Ethiopian Tigray due to depleted stocks, blame blockade https://scubadivetalks.com/doctors-say-lives-lost-in-hospitals-in-ethiopian-tigray-due-to-depleted-stocks-blame-blockade/ Wed, 05 Jan 2022 05:21:00 +0000 https://scubadivetalks.com/doctors-say-lives-lost-in-hospitals-in-ethiopian-tigray-due-to-depleted-stocks-blame-blockade/ Ethiopia’s largest hospital has not been restocked since June Doctors say patients are dying due to drug and equipment shortage All children admitted show signs of malnutrition NAIROBI, January 5 (Reuters) – At Ethiopia’s largest hospital in Tigray, a child injured in an airstrike died of blood after doctors ran out of gauze and intravenous […]]]>
  • Ethiopia’s largest hospital has not been restocked since June
  • Doctors say patients are dying due to drug and equipment shortage
  • All children admitted show signs of malnutrition

NAIROBI, January 5 (Reuters) – At Ethiopia’s largest hospital in Tigray, a child injured in an airstrike died of blood after doctors ran out of gauze and intravenous fluids. A baby died because there were no fluids for dialysis.

Doctors at the Ayder Referral Hospital in the regional capital Mekelle, which is under the control of Tigrayian forces fighting the central government, told Reuters by telephone that the lack of supplies was largely the result of a blockade of government assistance for several months in the northern region.

“Signing death certificates has become our main task,” the hospital said in a presentation Tuesday prepared for international aid agencies and shared with Reuters.

Register now for FREE and unlimited access to Reuters.com

Notes and materials for the presentation included case summaries, lists of missing drugs and medical supplies, and photographs of injured and malnourished patients. Reuters also interviewed three medics, who asked not to be identified for fear of reprisals from the Ethiopian authorities.

Doctors identified 117 deaths and dozens of complications, including infections, amputations and kidney failure, which they said were linked to shortages of essential drugs and equipment. They did not provide dates for most of them.

War erupted in November 2020 after the collapse of relations between Prime Minister Abiy Ahmed and the Popular Front for the Liberation of Tigray (TPLF), the party that dominated national politics until Abiy’s appointment and controls the major part of the region. The conflict has killed thousands of people and driven millions more from their homes.

Government spokesman Legesse Tulu reiterated Ethiopia’s position on Monday that no blockade had been imposed. He did not respond to questions about the shortages reported by Ayder.

“What is happening in Tigray now is the sole responsibility of TPLF,” Legesse told Reuters.

He accused the TPLF of looting equipment and medicine from more than a dozen hospitals and 100 health centers when its forces invaded neighboring areas of Amhara and Afar last year before moving on. be postponed until December.

A spokesperson for the TPLF declined to comment. The TPLF has previously denied looting of health facilities and blamed the government for the shortage of humanitarian supplies.

Ethiopia’s health minister also made no comment.

Ethiopia’s health minister and a TPLF spokesperson did not respond to requests for comment. The TPLF has previously denied looting of health facilities and blamed the government for the shortage of humanitarian supplies.

The United Nations first sounded the alarm over the lack of access to Tigray in December 2020, when government forces took control of Mekelle after fighting rebel forces loyal to the TPLF for three weeks.

Access for its trucks has fluctuated since then, but has declined significantly after government forces withdrew from most of the region in late June, according to reports by United Nations humanitarian agency OCHA.

Abiy’s government has repeatedly rejected accusations by the United Nations and other aid organizations that it is preventing humanitarian supplies from reaching Tigray.

The government has restricted access to the media since July. Some aid agencies have been banned and most communications with the region are down.

Two international aid agencies contacted by Reuters did not respond to requests for comment on Tuesday’s presentation, which was issued on behalf of all staff at Ayder Hospital.

‘FACT BLOCK’

A senior Ayder doctor told Reuters that around 80 to 90 percent of hospitals and clinics in Tigray are not functioning. According to the United Nations, more than 90% of the 5.5 million inhabitants of the region are in need of humanitarian assistance and 400,000 live in conditions bordering on famine.

Some supplies reached major towns in Tigray in the first eight months of the conflict, when the region was under government control. But little food and almost no medical supplies have arrived since the government pulled out in late June, doctors said.

They blamed what UN and US officials described as a de facto government blockade. The United Nations estimates that at least 100 aid trucks must enter Tigray every day to meet the needs. Less than 12% of that amount has arrived since July, OCHA said last week.

There are three main routes to Tigray, but bridges along two of them blew up when the Ethiopian military withdrew, according to OCHA reports. Convoys attempting to use the remaining overland route, via Afar, have faced lengthy security checks and bureaucratic delays that can last for weeks. Authorities often ban the passage of fuel and medicine, according to OCHA reports.

In late December, Afar authorities unloaded and distributed aid supplies from five of 20 trucks that had been waiting two weeks in the Afar border town of Abala for permission to enter Tigray, according to an OCHA report.

The World Food Program told Reuters it would run out of food and fuel in Tigray by mid-January.

Afar regional government spokesman Ahmed Koloyta did not respond to requests for comment. Government spokesman Legesse said the trucks entering Tigray had not returned and were being used by Tigray forces.

FAMINE

Ayder has not received a resupply of drugs or equipment since June, the three medics told Reuters. The 500-bed hospital is running out of everything from oxygen to antibiotics to therapeutic foods for malnourished children, they said. His scanners no longer work.

The percentage of children under 5 admitted for severe malnutrition almost doubled to over 41% in October.

Surafeal Mearig, 3 months old, weighed 3.4 kg at birth but now weighs 2.3 kg, according to hospital records. A photograph shared by his parents shows his protruding ribs, eyes sunk into his skull.

A pediatrician said the boy’s parents made a good living before the war. The father worked as a cashier in a construction company and his mother in a bank. Neither is working now, according to the case notes.

The breast milk has dried up and they cannot buy formula, the pediatrician said. The hospital will soon run out of food.

About 82% of essential drugs were available at the hospital a year ago, up from 17.5% at the end of 2021, the documents say. Among those who are depleted are insulin, oxygen, and most cancer drugs.

A malnourished baby girl arrived from Abi Adi town with pneumonia and kidney disease, the notes said. The hospital could not give him dialysis because there was no more intravenous fluids. She was one of 35 deaths among dialysis patients since the start of the war. The dialysis department said it was reusing equipment for one in five patients.

A doctor told Reuters he saw trauma patients succumb to fatal infections because most antibiotics were used up. He recounted the case of an 8-year-old girl who arrived on December 12 with a head injury after the emergency department ran out of gauze, gloves and painkillers.

Staff first used their bare hands to try to stop the bleeding, and eventually got some stitches from another ward, but there was no intravenous fluids or blood for a transfusion. She died in her mother’s arms, according to the case notes.

The girl’s mother told hospital staff she was injured in a government airstrike on Mekelle as she watched cartoons at her home, a doctor said in the notes.

Reuters could not independently confirm the account. Military spokesman Col. Getnet Adane did not respond to requests for comment, but previously denied that the government was targeting civilians.

Register now for FREE and unlimited access to Reuters.com

Katharine Houreld reported from Nairobi and Giulia Paravicini from Milian; Dawit Endeshaw contributed reporting from Addis Ababa; edited by Alexandra Zavis, Angus MacSwan and Howard Goller

Our standards: Thomson Reuters Trust Principles.


Source link

]]>
DTI Sec. Lopez says alleged drug shortages are not a concern │ GMA News Online https://scubadivetalks.com/dti-sec-lopez-says-alleged-drug-shortages-are-not-a-concern-%e2%94%82-gma-news-online/ Mon, 03 Jan 2022 05:38:52 +0000 https://scubadivetalks.com/dti-sec-lopez-says-alleged-drug-shortages-are-not-a-concern-%e2%94%82-gma-news-online/ Commerce Secretary Ramon Lopez said on Monday that no drug shortages have been reported in the country so far amid rising COVID-19 cases, unlike reports circulating online claiming the scarcity of drugstore supplies. According to Lopez, the Department of Trade and Industry (DTI) has not yet received any reports of a shortage, especially for paracetamol. […]]]>

Commerce Secretary Ramon Lopez said on Monday that no drug shortages have been reported in the country so far amid rising COVID-19 cases, unlike reports circulating online claiming the scarcity of drugstore supplies.

According to Lopez, the Department of Trade and Industry (DTI) has not yet received any reports of a shortage, especially for paracetamol.

“Wala po kaming natatanggap na shortage report, lalo na ‘yung mga paracetamol. Wala ho, ang dami ho niyan, tsaka ang dami pang generics niyan, so hindi po concern ‘yun, ”he said at Laging Handa’s public briefing.

[We have not yet received any reports on the shortage, especially for paracetamol. None, we have a lot of supplies of that, a lot of generic branded paracetamol, so that is not a concern.]

Lopez was asked about the drug supply because a number of online posts showed pharmacies were out of several flu and cold medications.

The Commerce Secretary also assured that there were sufficient oxygen tanks as part of the return to Alert Level 3 in Metro Manila, given the increase in COVID-19 cases.

“I hope the Omicron cases would be severity cases, Hindi malala and need oxygen,” he said.

[Hopefully these Omicron cases would not reach severity and would not get worse that would need oxygen.]

The National Capital Region returned to Alert Level 3 from Monday, January 3, which will last until January 15, 2022, following the sharp rise in new COVID-19 infections in the country.

The Philippines recorded an additional 4,600 confirmed cases of COVID-19 on Sunday, bringing the country’s number of active cases to 21,418. The total number of cases now stands at 2.851 million, including 2.778 million recoveries and 51,570 deaths. —KG, GMA News


Source link

]]>
Taking ibuprofen with naproxen may cause bleeding https://scubadivetalks.com/taking-ibuprofen-with-naproxen-may-cause-bleeding/ Sat, 01 Jan 2022 13:03:49 +0000 https://scubadivetalks.com/taking-ibuprofen-with-naproxen-may-cause-bleeding/ Compared to prescription drugs, over-the-counter (OTC) drugs tend to have fewer side effects. However, just because they are considered safe to consume does not mean that they can always be safely combined. Experts from the UK’s National Health Services (NHS) and the American College of Medical Toxicology (ACMT) say that in particular, there are two […]]]>

Compared to prescription drugs, over-the-counter (OTC) drugs tend to have fewer side effects. However, just because they are considered safe to consume does not mean that they can always be safely combined. Experts from the UK’s National Health Services (NHS) and the American College of Medical Toxicology (ACMT) say that in particular, there are two drugs that you should never take together. They warn that it could cause several different forms of bleeding, among other side effects. Read on to find out which over-the-counter medications should never be combined without a doctor’s go-ahead and what side effects you might experience if you do.

RELATED: Never Take These 2 Common Over The Counter Drugs At Once, Experts Warn.

Shutterstock

Experts say that combining ibuprofen drugs like Advil or Motrin with naproxen drugs like Aleve can cause a serious side effect – bleeding. This is because all of these drugs are classified as nonsteroidal anti-inflammatory drugs (NSAIDs), which are commonly used to relieve pain, reduce inflammation, and lower temperature. These over-the-counter drugs work the same in the body, which means that taking more than one drug at the same time doubles the risk of side effects. These can “range from mild nausea to severe gastrointestinal bleeding, ” Tim davis, PharmD, member of the National Community Pharmacists Association, recounts Prevention.

The NHS, which advises you never take naproxen with ibuprofen or other NSAIDs, says that you can experience this bleeding in one of several ways. They say some patients have reported “vomiting blood or dark particles that look like coffee grounds”, as well as blood in their stool, which “could both be signs of bleeding and perforation of the stomach. or intestines “.

Additionally, you may notice blood in your urine as well as a decrease in the amount of urine you pass urine. This can be a sign of kidney damage, which can be a side effect of naproxen in extreme cases.

RELATED: If You Do This Common Thing With Your Pills, Get Your Liver Checked Now.

Close-up of elderly man suffering from stomach pain while having breakfast with his wife
iStock

According to the NHS, you may experience several side effects when taking naproxen, even on its own. Most often, it is confusion, headache, ringing in the ears, blurred vision, fatigue, dizziness, or rash. In more rare cases, you may also experience severe indigestion, stomach pain, frequent sore throat, nosebleeds, recurrent infections, signs of anemia, fever, slowed rhythm cardiac, etc.

Shutterstock

The American College of Medical Toxicology echoes the NHS warning: “You can’t take several types of NSAIDs at the same time, ”warn their experts. “You have to decide which drug to use and only use that drug, unless you switch completely. It is important to always read the labeling of over-the-counter medications to avoid taking multiple products containing NSAIDs at the same time, ”adds ACMT.

Davis suggests that if you must are taking two NSAIDs as your doctor tells you to, you should spread them out to minimize the risk of side effects. He says if your symptoms are not corrected by this strategy, you should speak with your doctor about alternative medications that may be available to you.

For more health information sent straight to your inbox, sign up for our daily newsletter.

Woman talking to doctor
Shutterstock

The ACMT notes that there are many over-the-counter and prescription drugs other than ibuprofen that are classified as NSAIDs, some of which are based on ibuprofen and others are based on naproxen. Although this list is not exhaustive, “the brand names of some of these drugs include Advil®, Bayer Select®, Dayquil Sinus®, Dimetapp Sinus®, Dristan Sinus®, Excedrin IB®, IBU®, Motrin®, Motrin IB, Nuprin®, Pamprin® and Aleve® ”, explains the organization.

Besides the increased risk associated with the combination of ibuprofen and naproxen – or two NSAIDs, for that matter – the NHS notes that there is also a risk of side effects when taking naproxen with aspirin, blood thinners, some steroids, water pills, antidepressants, some heart medications, and some medications used to treat rheumatoid arthritis.

Speak with your doctor if you are at all concerned about your risk for a dangerous over-the-counter drug interactions involving any of these drugs.

RELATED: If You’re Over 60, Don’t Take This Over-The-Counter Drug Every Day, Officials Say.


Source link

]]>
Drug prices skyrocket – NewZimbabwe.com https://scubadivetalks.com/drug-prices-skyrocket-newzimbabwe-com/ Wed, 29 Dec 2021 04:48:17 +0000 https://scubadivetalks.com/drug-prices-skyrocket-newzimbabwe-com/ per press day ZIMBABWEAN drug retailers sell drugs at exchange rates between US $ 1: $ 220 and US $ 1: $ 230, raising fears that the industry could become one of the drivers of a massive depreciation of the market. the national currency. The Zimbabwean dollar was trading at around $ 1 to $ […]]]>

per press day


ZIMBABWEAN drug retailers sell drugs at exchange rates between US $ 1: $ 220 and US $ 1: $ 230, raising fears that the industry could become one of the drivers of a massive depreciation of the market. the national currency.

The Zimbabwean dollar was trading at around $ 1 to $ 110 when the foreign currency auction system closed for the holiday season two weeks ago.

This means drug retailers sell essential products at exchange rates that are more than double the official US dollar exchange rate.

Consumers find it difficult to purchase essentials like food and medicine due to the difficult economic climate resulting from hyperinflation and shortages of foreign currency.

A new wave of price increases supported by currency weaknesses could worsen an already difficult situation.

Reserve Bank of Zimbabwe (RBZ) Governor John Mangudya told NewsDay Business on Monday that authorities have set up cheaper financing kiosks for pharmaceutical retailers.

He said most of the foreign currency obtained through the arrangement had not been used.

Foreign currency acquired through the official system is cheaper.

The system was put in place by the government to give critical industries like the pharmaceutical sector easy access to finance.

“We have a facility for the pharmaceutical industry to access foreign currency,” Mangudya said.

“But adoption has been low for this facility, so in the coming weeks we will meet with them to find out why they are using such exchange rates,” Mangudya said.

However, pharmaceutical retailers blamed the wholesalers.

Pharmaceutical Society of Zimbabwe president Portifa Mwendera said drug retailers are not importers and only pass costs on to consumers on the basis of the prices at which they buy the drugs from wholesalers.

“What I do know is that retail pharmacies are not very keen on importing drugs, so they are not more involved in the forex market auction system,” Mwendera said.

“Even if you look at the list of those who got forex in the last 18 months, retail pharmacies are in the minority.

“You might find four or five pharmacies that are there because retail pharmacies are not inherently responsible for importing drugs.

“So what they do next is mainly apply a markup on the price that they would have bought the product from a wholesaler.

“It is the wholesaler who determines the exchange rate he uses for a product. And most exchange rates are implied, ”Mwendera added.

Before Christmas, former finance minister and MDC Alliance vice-chairman Tendai Biti warned that the exchange rate could reach US $ 1: $ 500 in the parallel market.

“Today, the US rate was trading between US $ 1: $ 220 and US $ 1: US $ 230. In a few months, it will reach $ 1: $ 500. A rate hike has dramatic inflationary consequences, ”Biti warned.

The black market exchange rate climbed 27% in the third quarter (3Q) of this year, marking its strongest growth on record in a year, researchers from Inter Horizon Securities (IH) said.

“Month-over-month inflation trended upward for the quarter, possibly in response to increased government spending on agricultural inputs,” IH said.

“The parallel market has been considerably volatile, gaining 27% for the quarter, the highest quarterly gain since 2Q20.

“As a result, the parallel market premium closed 3Q21 at 98% vs. 59%.

“On the Zimbabwe stock exchange, the All-Share index trended higher, outperforming 2Q21,” IH noted.


Source link

]]>
Civilians pay the price in Iraq as Mafia-run drug trade sees prices skyrocket https://scubadivetalks.com/civilians-pay-the-price-in-iraq-as-mafia-run-drug-trade-sees-prices-skyrocket/ Mon, 27 Dec 2021 09:04:32 +0000 https://scubadivetalks.com/civilians-pay-the-price-in-iraq-as-mafia-run-drug-trade-sees-prices-skyrocket/ Iraqi citizens bear the brunt of escalating medical costs, as the government fails to crack down on the mafias controlling the medical trade in the country or support the sorely neglected local pharmaceutical industry. Rising drug prices in Iraq are preventing many people from affording what was previously provided free. As mafia-like networks linked to […]]]>

Iraqi citizens bear the brunt of escalating medical costs, as the government fails to crack down on the mafias controlling the medical trade in the country or support the sorely neglected local pharmaceutical industry.

Rising drug prices in Iraq are preventing many people from affording what was previously provided free. As mafia-like networks linked to influential political actors control the import, distribution and price of drugs, Iraqi officials warn that the Ministry of Health is unable to offer an effective solution to the unfolding humanitarian crisis .

This year, drug prices have seen a sharp increase due to the rising dollar exchange rate and the Covid-19 pandemic, among other factors. As a result, dozens of deaths were recorded in hospitals across the country as critically ill patients could not afford the drugs they needed and were forced to search on the black market.

Despite the gravity of the situation, the health ministry has not pushed for concrete proposals to tackle the problem. According to a health official who preferred to remain anonymous, “the ministry is monitoring the case and plans to tackle the situation by coordinating with the security services. He also ran campaigns targeting drugstore owners, demanding that they cap the prices of various drugs. . However, these campaigns have not yet had much effect on prices. “

“Rising drug prices in Iraq are preventing many people from paying for what was previously provided for free”

Unscrupulous traders controlling the drug market

He continues, in a conversation with Al-Araby Al-Jadeed, The New Arabic Sister publication in Arabic: “This problem has been around for years, and at the moment the country is effectively dependent on drug traffickers who control imports according to demand. “

He pointed out, “Relying on these traders has left the ministry powerless to control the prices or quality of drugs in the country, a huge amount of which is produced without monitoring or complying with any kind of health regulations.

“The ministry has plans to reform the system, which focus on increasing government imports and repairing the health system so that free medicines are again provided in hospitals and health centers. However, it takes time and substantial funding to implement.

Lack of government oversight along with ministerial corruption has led to a drug crisis in Iraq’s healthcare sector [Ahmad Al-Rubaye/AFP via Getty]

Despite the ministry’s campaigns targeting pharmacies, around 70 percent of drugs sold in Iraq (many imported from European and Western manufacturers) are not subject to these controls.

MP Amer Al-Fayez confirms that the problem has become critical and requires rapid treatment: “The problem is dominated by mafias who control the importation as well as the distribution to drug suppliers and pharmacies, exploiting the lack of control government. This allowed them to set the prices as high as they wanted without worrying about the citizens.

“The problem requires serious action by the ministry – not just lip service. The government must appoint a special task force to monitor and pursue this problem from start to finish – from the time of importation through. sale to citizens. There must also be a strong accountability mechanism for those who break the law and penalties must be enforced. “

“The problem is dominated by the mafias who control importation as well as distribution to medical providers and pharmacies, exploiting the lack of government oversight.”

The disappearance of the Iraqi pharmaceutical industry

He mentions the disappearance of the Iraqi pharmaceutical industry, stressing that “Iraqi factories were manufacturing drugs and that Iraq had a certain degree of self-sufficiency in this area. However, today they are struggling and need the support of the government. Not only that, but bespoke plans need implementation to help them increase their production in a way that will support the local healthcare market with some of the drugs it needs. “

The Iraqi Pharmacists Union criticized the ministry’s plans, insisting the problem would not be solved by attempts to investigate pharmacies alone. Samer Khalidi, a union member, said: “They always focus only on pharmacies. And yes, that can be part of the solution – but it is by no means enough.”

Need a complete solution

Khalidi further explains: “The problem requires a comprehensive approach, starting with import contracts. Then, they must implement quality control on drugs, cover the needs of hospitals in terms of free drugs and support the pharmaceutical industry sector in the country. for this they need to crack down on the ministry’s corruption around medical contracts, and after all that comes the step of forming teams to monitor and investigate pharmacies in order to cut prices – pharmacies are the last link in the chain. when it comes to price escalation. “

He added: “We are not denying that many pharmacies are exploiting the situation, however, it is essentially the traders who control the prices. Without a plan to tackle the problem comprehensively, there is no chance that drug prices can be brought under control, and the health ministry is responsible. ”

Ministry corruption

The Iraqi Integrity Commission (an independent commission that investigates corruption in the Iraqi government) has repeatedly reported cases of corruption involving the purchase of drugs and medical supplies within the ministry.

Last month, the commission announced the seizure “of a large quantity of expired drugs which entered Dhi Qar province, the expiration dates of which have been falsified.”

The commission also recorded an incident of corruption in Maysan province where attempts to sell medical equipment at “prices well above market costs” were detected and prevented.

An additional factor that contributed to the sharp rise in drug prices was the decision of the Ministry of Finance to devalue the Iraqi currency in December 2020 – the exchange rate rose from 1,200 Iraqi dinars to $ 1 to 1,450 dinars at $ 1. Today, the exchange rate has fallen again to 1,480 dinars to $ 1.

Soaring drug costs are one of Iraq’s major problems today, and as hospitals suffer from a severe shortage of medical supplies, Iraqi patients bear the cost of purchasing imported drugs. in pharmacies at exorbitant prices.

This is an edited translation of our Arabic edition. To read the original article, click here.

Translated by Rose Chacko



Source link

]]>